WestVac Biopharma (Guangzhou) Co., Ltd. has made groundbreaking progress on the development of the world’s first trivalent recombinant protein COVID-19 vaccine against the latest prevalent subvariants including XBB.1.5 and BA.5. With the support of the National Key R&D Program of China and the NMPA’s clinical trial approval, this innovative vaccine is set to revolutionize the fight against the novel coronavirus.
WestVac Biopharma (Guangzhou) is on the frontline of the fight against COVID-19, utilizing their advanced insect cell expression platform to create a trivalent recombinant protein vaccine. This entirely synthetic vaccine has been precisely designed to target the S-RBD and HR proteins of XBB.1.5 and BA.5 subvariants, forming stable trimeric protein particles. Studies have revealed that the vaccine induces high titers of neutralizing antibodies against Omicron XBB.1.5, BQ.1, BF.7, BA.5, BA.2.75 and other subvariants, making it a broad-spectrum vaccine that is effective against multiple prevalent subvariants. WestVac Biopharma is working hard to meet all the national approval requirements and make the vaccine available to the public as soon as possible. Let’s join forces with WestVac Biopharma in this fight against the new variants of the novel coronavirus!
WestVac Biopharma Co., Ltd. is an innovative biopharmaceutical company that has been honored as one of the unicorn companies for two consecutive years! The company has developed Coviccine® –Recombinant COVID-19 Vaccine (Sf9 cell), which has been approved by the national authority for emergency use with a 70.95% protective efficacy against Omicron subvariants. Moreover, the Recombinant Variant COVID-19 vaccine (Sf9 cell) also received the Approval for Clinical Trial by NMPA and is soon to enter Phase I/II clinical trials. Vaccination for multiple provinces has already begun and the results are looking promising! WestVac Biopharma will continue to strive for innovating and improving the lives of people everywhere.